Dimethylaminomicheliolide (DMAMCL) Suppresses the Proliferation of Glioblastoma Cells via Targeting Pyruvate Kinase 2 (PKM2) and Rewiring Aerobic Glycolysis

Jianshuang Guo 1, Qingqing Xue 1, Kaihui Liu 1, Weizhi Ge 1, Wenjie Liu 1, Jiyan Wang 1, Mengyi Zhang 1, Qiu-ying Li 1, Dongpo Cai 2, Changliang Shan 1, Chunze Zhang 3, Xinqi Liu 4 and Jing Li 1*

1 State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China, 2 Accendatech Co., Ltd., Tianjin, China, 3 Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, China, 4 State Key Laboratory of Medicinal Chemical Biology, College of Life Science, Nankai University, Tianjin, China

Glioblastoma (GBM) is the most prevalent malignant tumor in the central nervous system. Aerobic glycolysis, featured with elevated glucose consumption and lactate production, confers selective advantages on GBM by utilizing nutrients to support rapid cell proliferation and tumor growth. Pyruvate kinase 2 (PKM2), the last rate-limiting enzyme of glycolysis, is known to regulate aerobic glycolysis, and considered as a novel cancer therapeutic target. Herein, we aim to describe the cellular functions and mechanisms of a small molecular compound dimethylaminomicheliolide (DMAMCL), which has been used in clinical trials for recurrent GBM in Australia. Our results demonstrate that DMAMCL is effective on the inhibition of GBM cell proliferation and colony formation. MCL, the active metabolic form of DMAMCL, selectively binding to monomeric PKM2 and promoting its tetramerization, was also found to improve the pyruvate kinase activity of PKM2 in GBM cells. In addition, non-targeting metabolomics analysis reveals multiple metabolites involved in glycolysis, including lactate and glucose-6-phosphate, are decreased with DMAMCL treatment. The inhibitory effects of DMAMCL are observed to decrease in GBM cells upon PKM2 depletion, further confirming the importance of PKM2 in DMAMCL sensitivity. In conclusion, the activation of PKM2 by DMAMCL results in the rewiring aerobic glycolysis, which consequently suppresses the proliferation of GBM cells. Hence, DMAMCL represents a potential PKM2-targeted therapeutic agent against GBM.

Keywords: dimethylaminomicheliolide, glioblastoma, PKM2 activator, aerobic glycolysis, lactate production

INTRODUCTION

Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor, with a survival rate of 6–9 months after diagnosis (1, 2). Surgical resection followed by concomitant radiotherapy and chemotherapy with the DNA alkylating agent temozolomide (TMZ), is the routine treatment for GBM (3). However, the median survival of treatment with TMZ only increased up to 14.6 months comparing to 12.1 months with radiotherapy alone (2, 4). Therefore, new treatment approaches and novel therapeutic targets are desperately needed for the treatment of GBM (5–7).
The aerobic glycolysis, characterized by increased glucose uptake and lactate production, is a prominent feature of cancer. Global metabolomic profiling on 69 fresh-frozen glioma specimens has revealed that GBMs have accelerated aerobic glycolysis by the accumulation of the glycolytic intermediate phosphoenolpyruvate (PEP) and decrease in pyruvate kinase (PK) activity (8). PK is the last irreversible glycolytic enzyme that catalyzes the reaction of generating pyruvate and ATP from PEP and ADP (9). There are two PKM genes (PKLR and PKM) and four PK isoforms (L, R, M1, M2) in mammals (9). PKM1 primarily expresses in the brain and muscle while PKM2 specifically expresses in embryonic cells, adult stem cells, and tumor cells. In contrast to the active tetrameric PKM1, PKM2 exists in equilibrium between low activity monomers/dimers and highly active tetramer. This equilibrium is regulated from PEP and ADP (i.e., ACT001), the fumarate salt form of dimethylamino MCL (MCL and DMAMCL were synthesized as previously reported (25). Briefly, U118MG cells were plated on a 10 cm tissue culture dish and grown to the confluence for 24 h. Cells were harvested and lysed in RIPA buffer [50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and sodium orthovanadate, sodium fluoride, EDTA, leupeptin, etc.] with protease inhibitors and the total protein concentration was quantified with BCA assay (Thermo Fisher Scientific, Waltham, MA). The normalized samples were analyzed by SDS-PAGE and western blot using standard.
FIGURE 1 | DMAMCL reduces the proliferation of malignant glioma cells and the colony formation through release MCL. (A) The release of MCL from DMAMCL. In HEPES buffer, pH = 7.4 or mouse plasma, DMAMCL slowly release MCL. The \(\alpha\)-methylene-\(\gamma\)-lactone group of MCL are able to act as a Michael acceptor to form a covalent bond with the thiol group of cysteine residue. (B–F) U118MG, U251MG, SF126, SHG44, U87MG cells were grown and treated with DMAMCL at 0–40 \(\mu\)M for 24, 48, and 72 h, respectively. The number of cells was counted. (G) Representative malignant glioma colony formation assays from four different cell lines treated with DMAMCL at 0–10 \(\mu\)M for 14 days. (H) The statistic of the relative colony formation efficiency. Error bars, mean \(\pm\) s.e.m., \(n = 3\) biological replicates. *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\).
protocols and the following primary antibodies: anti-PKM1 (1:1,000 dilution, sigma, SAB4200094), anti-PKM2 (1:1,000 dilution, Cell Signaling, 4,053), and anti-actin (1:2,000 dilution, Cell Signaling, 4,970), the secondary antibodies: Anti-rabbit IgG, HRP-linked antibody (1:3,000 dilution, Cell Signaling, 7,074). Results are represented as mean and s.e.m. of at least three independent experiments.

PKM2 Activity Assay
Pyruvate kinase activity was measured as previously described (27). Briefly, for cell line experiments, the medium was replaced with fresh medium 1 h prior to the start of treatment with DMAMCL. Where indicated, 100 µM pervanadate was added 10 min prior to cell lysis. Cells were lysed on ice with NP-40 buffer containing 2 mM DTT and protease inhibitors, then clarified by centrifugation at 12,000 rpm. Pyruvate kinase activity in lysates was determined by the pyruvate kinase assay kit (17). Results are represented as mean and s.e.m. of at least three independent experiments.

Lactate Production Assay
Extracellular lactate production was measured with Lactate Colorimetric/Fluorometric Assay Kit (BioVision). The cells were seeded in a 6-well plate, and after 24 h, cells were treated with DMAMCL for 24 h, the medium was replaced with Opti-MEM and incubated for 1 h at 37°C. After incubation, the medium from each well was assessed using the lactate assay kit. The cell numbers were count for statistical analysis. Results are represented as mean and s.e.m. of at least three independent trials.

Lentiviral Transduction
The lentiviral transduction was performed as we previously described (17). The shRNA for PKM2 was 5′-CCATAATCGTCTCCTACCAA-3′; the shRNA for negative control was 5′-CUUACGCUGAGUACUUGC-3′ (28, 29).

RNA Isolation and Quantitative Real-Time PCR for mRNA
The total RNA was extracted by applying TRIzol reagent (Takara) according to the manufacturer’s protocol. Immediately after isolation, RNA quantity and quality were determined by using NanoDrop spectrophotometer (Thermo Fisher Scientific), 1,000 ng of total RNA was reversely transcribed using the First Strand cDNA Synthesis kit (Takara). The quantitative PCR analysis was performed in the Real-time Detection System (QuantStudio TM 6) by SYBR Premix Ex Taq II kit (Takara). The sequences of primers are PKM2 forward: GAGCCACACTCACCTACT, PKM2 reverse: CAGGACCTGCTCAAACACACT, PKM2 forward: GAGGGTTGGTTCGCC, PKM2 forward: GACTGGTTGGTACCCAC, GAPDH forward: ATCCGT GGCTACACTGAGCA, GAPDH reverse: ATGAGGTTCCACCCTGT; ENO forward: AAAGCTGGTGCCGTTG AGAA, ENO reverse: GGTGGTGAAACCTCTGCTC; PFK2 forward: ATGCAGAAGCCCATATGAA, PFK2 reverse: TGGGTTGTAACTATGTCCA; LDHA forward: ATGGCAACTTAAAGGATCAGC, LDHA reverse: CCAACCCCCAAACTGTAAT; β-actin forward: GGAAATCGTGGCTGAC AT; β-actin reverse TGCCATGTGATGACCT. The PCR amplifications were performed at 95°C for 30 s, followed by 40 cycles of thermal cycling at 95°C for 5 s and 60°C for 45 s.

Size Exclusion Chromatography
Size exclusion chromatography was performed to isolate PKM2 in different aggregation states. Aliquots of 2 mL of 3 mg/mL purified PKM2 were loaded into a Superdex 200 pg 16/600 column (GE). Two milliliter sample was injected, and the column flow rate was maintained at 1 mL/min. Protein peaks were monitored using the UV absorbance at 280 nm. The retention volumes for the PKM2 peaks were identified by analytical ultracentrifuge. Afterwards, samples were collected for each peak for further PKM2 activity assays. Results are represented as mean and s.e.m. of at least three independent experiments.

Metabolomics Analysis
For the metabolism measurement, U118MG cells were seeded in 10 cm culture dishes to obtain 80–90% confluence. Then the culture was changed to a fresh growth medium containing DMAMCL for 48 h. The cells were harvested and quenched with extraction buffer (methanol:water = 1:1). Prior to GC-MS metabolomics analysis, the metabolites were extracted and derivatized. Analysis of metabolites was performed on an Agilent 7890A/5975C GC-MS system (Agilent Technologies Inc., CA, USA). The derivatives were separated using an OPTIMA 5 MS Accent fused-silica capillary column (30 m × 0.25 m × 0.25 m; MACHEREY-NAGEL, Düren, GER). The peak picking, alignment, deconvolution, and further processing of raw GC-MS data were referred to the previous published protocols (30). The data were normalized against total peak abundances before performing univariate and multivariate statistics. The data was imported to SIMCA software (version 14.1, Umetrics), where multivariate statistical analyses, such as principal component analysis (PCA), partial least-squares-discriminant analysis (PLS-DA), and orthogonal partial least-squares-discriminant analysis (OPLS-DA) were performed. All data were mean-centered and unit variance (UV)–scaled prior to multivariate statistical analysis. The quality of the models is described by the R² values. Differential metabolites were determined by the combination of variable importance in the projection (VIP) value (>1) of the OPLS-DA model and the p-values (<0.05) from two-tailed student’s t-tests on normalized peak intensities (31).

Statistical Analysis
Statistical analysis and graphical presentation were done using GraphPad Prism 5.0. All data are presented as mean ± s.e.m. Results are representative examples of three individual experiments. P-values were determined by a two-tailed Student’s t-test.
RESULTS
DMAMCL Suppresses Proliferation and Colony Formation of Various Malignant Glioma Cells

To explore the mechanism of DMAMCL as an anti-cancer agent, we evaluated the growth curve of five glioma cell lines (U118MG, U251MG, U87MG, SF126, SHG44) with DMAMCL treatment. U118MG, U251MG, and U87MG are GBM cell lines, and SF126 and SHG44 are astrocytoma cell lines. The growth of five glioma cell lines was inhibited by DMAMCL treatment in a dose- and time-dependent pattern (Figures 1B–F). The IC50 values of DMAMCL against U118MG, U251MG, U87MG, SF126, SHG44 were 17.9, 22.1, 37.1, 25.2, 32.4 µM, respectively, at 48 h. Among them, U118MG and U251MG cells were more sensitive and showed around 80 and 70% decreased viability rate with 20 µM DMAMCL for 3 days. Similarly, MCL exhibited the same inhibiting effect at a lower concentration, the IC50 values of MCL against U118MG, U251MG, SF126 were 4.2, 14.5, 11.1 µM (Supplementary Figure 1). Furthermore, we investigated the effect of DMAMCL on the oncogenicity of glioma cells by soft agar assay. The results showed that DMAMCL could strongly suppress colony formation in U118MG, U251MG, SF126, SHG44 cells with IC50 values at 1.4, 1.2, 1.4, 2.8 µM (Figures 1G,H). These results suggest that DMAMCL markedly inhibits the proliferation of glioma cells. Therefore, GBM cell lines (U118MG and U251MG) were selected for further experiments.

MCL, the Active Metabolite of DMAMCL, Binds to PKM2 in GBM Cells

Pharmacokinetics studies of DMAMCL revealed that DMAMCL slowly but consistently releases MCL in the plasma and in vivo (32). MCL contains a typical α-methylene-γ-lactone group, which can react with accessible cysteine thiol groups to induce modifications of biological functions (33). Using synthesized biotin-conjugated MCL (MCL-biotin, Probe) and inactive probe (MCL-S-biotin, NC probe), we have proved that PKM2 was the primary target of MCL in leukemia cells. To validate whether the target of DMAMCL is PKM2 in GBM cells, we performed pull-down experiments in U118MG cells (Figure 2A) (17). The U118MG-cell lysates were incubated with Probe or NC probe, and the mixture was pulled down with streptavidin-coated agarose beads. The precipitated proteins were resolved by SDS-PAGE and silver staining. As shown in Supplementary Figure 2A, several bands were precipitated by Probe including a distinct band between 55 and 70 kDa. Peptide mass fingerprinting data analysis revealed that 5 peptides of PKM2 were detected in the mass spectrometry (Supplementary Figure 2B), which confirmed PKM2 was the main target of MCL. Immunoblotting was further used to monitor the presence of PKM2 in the precipitates. Consistently, PKM2 was pulled down by Probe, but not NC probe. The signal intensity of PKM2 band increased in a dose-dependent manner of Probe, indicating a strong interaction between Probe and PKM2 in glioma cells (Figure 2B). Moreover, we also observed that an excess of MCL could compete out the PKM2 bound on MCL-Biotin, resulting in the decline of the signal (Figure 2C).

Taken together, these results demonstrate that PKM2 is a direct target of DMAMCL in U118MG cells. Since MCL is a multi-target drug, we sought to further verify other potential targets besides PKM2 (data has not been published).

MCL Activates Monomer PKM2 Through C424 Binding Site in GBM Cells

Our previous work demonstrated MCL activates PKM2 through an irreversible covalent modification on the cysteine 424 residue (C424) of PKM2 in leukemic cells (17). Here, we produced recombinant PKM2 proteins and detected its enzymatic activity with the incubation of MCL for 90 min. As shown in Figure 2D, the PK activity was enhanced with the increasing treatment of MCL. It has been reported that recombinant PKM2 (rPKM2, expressed in E. coli) consists of monomer, dimer, and tetramer (34). In order to know which form of PKM2 binds to MCL, size-exclusion chromatography and sucrose gradient ultracentrifugation was used to separate rPKM2 into monomers/dimer, tetramer, and polymer (Supplementary Figure 3) (34). The isolated monomers and tetratomers were incubated with 10 µM MCL, respectively, and then PK activity was measured. PKM2 tetratomers showed higher enzymic activity than their monomeric counterpart with C424 mutation (PKM2 C424S) did not respond to MCL treatment in either monomeric or tetrameric forms, indicating the dependency of C424 during the MCL-induced PKM2 activation (Figure 2F). In addition, the particle size analysis was carried out to confirm the change of rPKM2, which displayed a significant aggregation of rPKM2 with MCL treatment (Supplementary Figure 4). These results indicate that MCL mainly binds to the monomeric PKM2 at C424 and promotes PK activity of PKM2.

DMAMCL/MCL Increased Intracellular PK Activity and Decreased Lactate Production in GBM Cells

To investigate whether DMAMCL increases the PK activity in cells, U118MG cells with DMAMCL treatment were assayed for PK activity. Consistent with the MCL results, DMAMCL also significantly increased the PK activity in U118MG cells (Figure 3A). As tetrameric PKM2 is the most active form (35), we sought to determine whether DMAMCL/MCL could increase the formation of tetrameric PKM2 in cells. U118MG cells were incubated with DMAMCL and MCL, respectively, and then the cell lysates were crosslinked with disuccinimidyl suberate (DSS), an unbreakable crosslinker for proteins. The samples were then resolved by SDS-PAGE, and followed by immunoblotting with anti-PKM2. As shown in Figures 3B,C, in the presence of DMAMCL or MCL, the concentration of tetrameric PKM2 significantly increased in accordance with a decrease of monomeric PKM2.

Based on previous studies, tumor cells preferentially express the less-active form of PKM2, which favors lactate production (35). To test whether DMAMCL decreases the
DMAMCL Treatment Inhibited Anaerobic Metabolism in GBM Cells

Previous studies have demonstrated PKM2 plays a key role in aerobic glycolysis, and that PKM2 activators could “starve” cancer cells of the biomolecular precursors required to support the rapid cell proliferation associated with metastatic growths (35). To further understand the mechanism of DMAMCL in GBM cells, we interrogated the effects of DMAMCL (10 µM, 48 h) on the cell metabolism. The metabolites (five repeats per treatment) were extracted and analyzed by GC-MS. The R²X of the PCA model with 2 principal components was >0.5, indicating a markedly different metabolism between the groups (Supplementary Figure 5A). The R²Y and Q² of the PLS-DA model were closer to 1, indicating the model is reliable for explaining and predicting the variations (Supplementary Figure 5B).

The results showed at least 35 metabolites (29 metabolites down-regulated and 6 metabolites up-regulated) that were significantly modified in the group of DMAMCL treatment (Supplementary Table 1). The variations were visualized with heat maps (Figure 4A) and Pearson correlation (Supplementary Figure 6), respectively. Most of the changes can be associated with alterations of the metabolism characteristics of glycolysis, pentose phosphate pathway and amino acid metabolism (Figure 4B). Elevated lactate production and glucose consumption are key features of aerobic glycolysis. As expected, DMAMCL induced a decrease of lactate and glucose-6-phosphate (the first transform of glucose catalyzed by hexokinase) (Figure 4C). In addition, the intracellular concentrations of sedoheptulose-7-phosphate and glycerol-3-phosphate also significantly decreases (Figure 4C). As reported, sedoheptulose-7-phosphate is a key intermediate for the biosynthesis of nucleotides through the pentose phosphate pathway. The glycolysis pathway was most significantly inhibited, to verify the effects of DMAMCL on the aerobic glycolysis enzymes, the U118MG cells were treated with 10 µM DMAMCL for 90 min.
and 20 µM DMAMCL for 48 h, and the mRNA expressions of enzymes including HK2, GPI, PFK, TPI, PGK, GAPDH, ENO, PKM2, LDHA were detected (Figure 4D). Consistent with metabolomics, most metabolic enzymes exhibited a dose-dependent decrease in DMAMCL. Taken together, DMAMCL impairs the survival and proliferation of GBM cells by rewiring aerobic glycolysis.

**Depleted Expression of PKM2 Decreased the Effects of DMAMCL on GBM Cell Viability**

PKM2 was reported to highly express in human glioma samples (14). Consistently, western blot analysis showed that PKM2 highly expressed in five human glioma cell lines (Figure 5A). Basically, DMAMCL did not affect the total protein level of PKM2 in U251MG cells (Figure 5B). In order to verify the importance of PKM2 in the DMAMCL-mediated inhibition of glioma cell viability, we constructed U251MG cell lines stably expressing short hairpin RNA (shRNA) for PKM2 (shPKM2) or control shRNA (shCtrl). Both PKM2 expression and the PK activity in shPKM2 cells were significantly decreased compared to those in shCtrl cells (Figures 5C,D). As shown in Figure 5E, after the addition of DMAMCL for 48 h, shPKM2 cells were less sensitive to the inhibitory effect of DMAMCL than shCtrl cells. However, knock-down the expression of PKM2 did not completely abrogate the effect of DMAMCL, which suggested that DMAMCL is a multi-target drug. Taken together, these results proved further evidence that the effect of DMAMCL on GBM cell viability is PKM2-dependent.

Collectively, these results demonstrated that DMAMCL/MCL inhibited cell proliferation and viability in GBM via direct interaction with PKM2. Promotion of tetramer formation in PKM2 likewise caused a downstream inhibition of anaerobic metabolism and anabolism (Figure 6). This provides effective insight regarding the mechanism for how DMAMCL in GBM treatment functions.

**DISCUSSION**

Altered metabolic pathways are one of the hallmarks of cancerous cells (36). Tumor cells mainly rely on aerobic glycolysis (high rates of glucose uptake and lactate production)
FIGURE 4 | DMAMCL treatment inhibited anaerobic metabolism and anabolism in U118MG cells. (A) Heat maps of identified differential metabolites in U118MG cells treated with DMAMCL-10µM (n = 5). (B) Differentiated metabolic pathway analysis with MetaboAnalyst 2.0 in U118MG cells treated with DMAMCL-10µM. (C) The glucose metabolism and the key metabolites (glucose-6-P, lactate, sedoheptulose-7-phosphate levels in U118MG cells treated with DMAMCL). (D) The mRNA expression of metabolic enzymes involved in aerobic glycolysis. Error bars, mean ± s.e.m., n = 3 biological replicates. **P < 0.01, ***P < 0.001, ns, no significant.
FIGURE 5 | The cell viability inhibition effect of DMAMCL is dependent on the expression of PKM2. (A) Western blot detection of PKM2 and PKM1 in different human glioma cell lines. (B) The expression of PKM2 with DMAMCL treatment was detected via western blot. (C) The depleted expression of PKM2 was confirmed by western blotting. (D) The PK activity of U251MG cells was detected with shCtrl and shPKM2 by PK activity assay. (E) Depleted expression of PKM2 resulted in a decreased inhibition effect of DMAMCL in U251MG cells after treatment for 48 h. Cell viability was determined by CCK8 assay. Error bars, mean ± s.e.m., n = 3 biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ns, no significant.

FIGURE 6 | The mechanism of DMAMCL and MCL on GBM inhibition through activating PKM2.
to produce energy even in the presence of oxygen (10, 37–39). Aerobic glycolysis contributes to cancer cell proliferation by providing the raw components required for to synthesis of cellular materials (40). Increasing evidences have shown that PKM2 plays a critical function in the maintenance of aerobic glycolysis, with decreased PK activity favoring cancer cell proliferation (15, 41, 42). Therefore, targeting PKM2 is a promising therapeutic strategy for the treatment of GBM.

DMAMCL is currently in clinical trials for the treatment of recurrent GBM and has been designated an orphan drug by FDA. Previous studies found a 98.6% inhibition of AML cells in engraft NOD/SCID murine model (24) and significant anti-malignant glioma activities in vivo (16). Using leukemic cell HL60, we have proved that MCL, the active metabolite of DMAMCL, binds the C424 residue of PKM2 and to promote PK activity (17).

In this study, we verified that DMAMCL suppressed the cell proliferation and colony formation across different glioma cell lines. GBM cells were found more sensitive to DMAMCL treatment than astrocytoma cells. By using biotin-conjugated probes, we successfully found that MCL directly targeted PKM2, and promoted the subunit association into the active tetramer in GBM cells. The metabolomics profile also demonstrated the majoritiy of the intermediates in glycolysis were reduced, consistent with increased PKM2 activity. Furthermore, depletion of PKM2 decreased the viability inhibition of DMAMCL on GBM cells, demonstrating PKM2 is a key target for DMAMCL in GBM. However, shPKM2 cells did not abrogate the whole effect of DMAMCL, which suggests that PKM2 may not be the sole target of DMAMCL. Thus, other targets of DMAMCL needed to be determined.

Recently, using two glioma cell lines (U87-MG and U251), Wang et al. discovered that DMAMCL decreased cell viability and induced apoptosis in glioma cells. Then subsequent experiments showed that the treatment of DMAMCL (40 μM) induced apoptosis and autophagy, which were possibly mediated by ROS generation and Akt/mTOR signaling pathway inhibition (18). The mechanism of drug is directly related to the concentration, incubation time and cell lines etc. Based on our unpublished data, under low concentration (< 20 μM), DMAMCL mainly inhibits the cell proliferation, however, under high concentration (20–40 μM), DMAMCL mainly induced apoptosis. In our view, these different mechanisms may due to different concentrations.

In conclusion, DMAMCL is an effective anti-cancer agent for suppressing the proliferation and colony formation in glioma cells, especially in GBM. Our research revealed a novel therapeutic strategy that uses DMAMCL/MCL to activate PKM2 in rewiring the aerobic glycolysis and further inhibit GBM cell growth. This highlights the biological target of DMAMCL for the clinical treatment of GBM.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the manuscript/Supplementary Files.

AUTHOR CONTRIBUTIONS

JG and JL contributed to the conception and design of the experiments. XL, CS, QX, QL, and JL developed the methods. WG synthesized the chemical. JG, QX, KL, WL, JW, and MZ performed the experiments and statistical analysis. JG wrote the paper. JL, MZ, and CS reviewed and revised the paper. DC and CZ provided technical and material support.

FUNDING

This work was supported by Accendatech Co., Ltd., and grants from the National Natural Science Foundation of China (81573282, 31000371), the National Science Fund for Distinguished Young Scholars (81625021), the Hundred Young Academic Leaders Program of Nankai University (for Yue Chen), the Opening Funds of Beijing National Laboratory for Molecular Sciences (BNLMS201826), the Fundamental Research Funds for the Central Universities of Nankai University (63191143, 63191125).

ACKNOWLEDGMENTS

We thank Kenneth Huang for correcting the grammar and scientific editing of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.00993/full#supplementary-material

REFERENCES

1. Thakkar JP, Dolcek TA, Horbinski C, Ostrom QT, Lightner DD, Barbaehrt-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. (2014) 23:1985–96. doi: 10.1158/1055-9965.EPI-14-0275
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. (2013) 310:1842–50. doi: 10.1001/jama.2013.280319
3. Whitehead CA, Nguyen HPT, Morokoff AP, Luwor RR, Paradiso L, Kaye AH, et al. Inhibition of radiation and temozolomide-induced invadopodia activity in glioma cells using FDA-approved drugs. Transl Oncol. (2018) 11:1406–18. doi: 10.1016/j.tranon.2018.08.012
4. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. (2006) 2:494–503; quiz 1 p following 516. doi: 10.1038/ncpneuro0289
5. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. (2014) 20:5612–9. doi: 10.1158/1078-0432.CCR-14-0834
6. Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol. (2014) 16:1575–84. doi: 10.1093/neuonc/nou147
7. Laks DR, Visnyei K, Kornblum HL. Brain tumor stem cells as therapeutic targets in models of glioma. Yonsei Med J. (2010) 51:633–40. doi: 10.3349/ymj.2010.51.5.633
8. Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S, et al. The metabolic signature of malignant glioma reflects accelerated anabolic metabolism. *Cancer Res.* (2012) 72:5878–88. doi: 10.1158/0008-5472.CAN-12-1572-T

9. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. *Clin Cancer Res.* (2012) 18:5554–61. doi: 10.1158/1078-0432.CCR-12-0859

10. Talekar M, Boreddy SR, Singh A, Amiji M. Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. *Expert Opin Biol Ther.* (2014) 14:1145–59. doi: 10.1517/14712598.2014.92270

11. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. *PLoS ONE.* (2013) 8:e57610. doi: 10.1371/journal.pone.0057610

12. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, et al. Pyruvate kinase M2 isoform expression alters nucleotide synthesis to impact cell proliferation. *Mol Cell.* (2015) 57:95–107. doi: 10.1016/j.molcel.2014.10.027

13. Hsu MC, Hung WC. Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling. *Mol Cancer.* (2018) 17:35. doi: 10.1186/s12934-018-0791-3

14. Babaei G, Aliarab A, Abroon S, Rasmiz A, Aziz SG. Application of sesquiterpene lactone: a new promising way for cancer therapy based on anti-cancer activity. *Biomed Pharmacother.* (2018) 106:239–46. doi: 10.1016/j.biopha.2018.06.131

15. Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorogenesis. *Nat Chem Biol.* (2012) 8:839–47. doi: 10.1038/nchembio.1060

16. Dong T, Li C, Wang X, Dian L, Zhang X, Li L, et al. Ainsliadimer A, a Nrf2 activator, targets the Akt/mTOR signaling pathway and suppressing the Akt/mTOR signaling pathway in glioma cells infected with classical swine fever virus. *Front Microbiol.* (2017) 8:6961. doi: 10.3389/fmicb.2017.00691

17. Xu XN, Liu N, Wang QQ, Wu HT, He HB, Wang LL, et al. Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. *J Chromatogr B Anal Technol Biomed Life Sci.* (2019) 1104:29–39. doi: 10.1016/j.jchromb.2018.11.004

18. Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, et al. Small molecule inhibitors of pyruvate kinase M2 irreversibly activate pyruvate kinase M2 and suppress leukemia. *Oncotarget.* (2014) 5:11622–11634. doi: 10.18632/oncotarget.26569

19. Xi XN, Liu N, Wang QQ, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. *Nat Rev Cancer.* (2011) 11:325–37. doi: 10.1038/nrc3038

20. Li J, Li S, Guo J, Li Q, Long J, Ma C, et al. Natural Product Michelolide (MCL) irreversibly activates pyruvate kinase M2 and suppresses leukemia. *J Med Chem.* (2018) 61:4155–64. doi: 10.1021/acs.jmedchem.8b00241

21. Wang Y, Zhang J, Yang Y, Liu Q, Xu G, Zhang R, et al. The ROS generation and autophagosome accumulation contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/AMPK signaling pathway and suppressing the Akt/mTOR signaling pathway. *Onco Targets Ther.* (2012) 6:1867–80. doi: 10.2147/OTT.S195329

22. Zhai JD, Li D, Long J, Zhang HL, Lin JP, Qiu CJ, et al. Biomimetic semisynthesis of arglabin from parthenolide. *J Org Chem.* (2015) 80:6522. doi: 10.1021/acs.joc.5b01295

23. Babaei G, Aliarab A, Abroon S, Rasmiz A, Aziz SG. Application of sesquiterpene lactone: a new promising way for cancer therapy based on anti-cancer activity. *Biomed Pharmacother.* (2018) 106:239–46. doi: 10.1016/j.biopha.2018.06.131

24. Hancock D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013

25. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. *Nat Rev Cancer.* (2011) 11:325–37. doi: 10.1038/nrc3038

26. Liu N, Wang QQ, Wu HT, He HB, Wang LL, et al. Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. *J Chromatogr B Anal Technol Biomed Life Sci.* (2019) 1104:29–39. doi: 10.1016/j.jchromb.2018.11.004

27. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature.* (2008) 452:230–3. doi: 10.1038/nature06734

28. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumour growth. *Proc Natl Acad Sci USA.* (2011) 108:4129–34. doi: 10.1073/pnas.1014769108